CRISPR will pay ViaCyte to treat Type I Diabetes in the most unconventional way. ViaCyte will utilize the stem cells to create special pancreatic cells. They are not cells that are compatible with the patient’s individual cells. The introduction of these special cells might trigger a rejection attack from the immune system. This is where CRISPR’s gene-editing technology steps in.
The said tech intends to change the special pancreatic cells into non-threatening ones. When this happens, the patient’s immune system will not attack them anymore.
CRISPR believes that their partnership with ViaCyte will accelerate their regenerative medicine efforts. This will hopefully bring forth long-term opportunities for them.
This venture with ViaCyte will produce less expensive Type I Diabetes treatments, since the special cells will be produced on a large scale.